S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:CRBP

Corbus Pharmaceuticals Stock Forecast, Price & News

$0.74
-0.08 (-9.76%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.70
$0.83
50-Day Range
$0.74
$1.11
52-Week Range
$0.70
$4.00
Volume
1.50 million shs
Average Volume
1.11 million shs
Market Capitalization
$92.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.82
30 days | 90 days | 365 days | Advanced Chart
Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Corbus Pharmaceuticals logo

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
Employees
76
Year Founded
N/A

Sales & Book Value

Annual Sales
$3.94 million
Book Value
$0.62 per share

Profitability

Net Income
$-111.27 million
Net Margins
-2,856.56%
Pretax Margin
-2,856.56%

Debt

Price-To-Earnings

Miscellaneous

Free Float
114,962,000
Market Cap
$92.67 million
Optionable
Optionable

Company Calendar

Last Earnings
11/12/2021
Today
12/05/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/21/2022

MarketRank

Overall MarketRank

1.74 out of 5 stars

Medical Sector

899th out of 1,388 stocks

Pharmaceutical Preparations Industry

426th out of 668 stocks

Analyst Opinion: 3.1Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

Is Corbus Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals
or view top-rated stocks.

How has Corbus Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRBP shares have decreased by 82.0% and is now trading at $0.74.
View which stocks have been most impacted by COVID-19
.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Corbus Pharmaceuticals
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced its quarterly earnings results on Friday, November, 12th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.10. Corbus Pharmaceuticals had a negative net margin of 2,856.56% and a negative trailing twelve-month return on equity of 60.39%.
View Corbus Pharmaceuticals' earnings history
.

What price target have analysts set for CRBP?

4 brokers have issued twelve-month target prices for Corbus Pharmaceuticals' stock. Their forecasts range from $2.00 to $3.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 237.8% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:
  • Yuval Cohen, Chief Executive Officer & Director
  • Craig Millian, Chief Operating Officer
  • Sean F. Moran, Chief Financial & Accounting Officer
  • Dylan Wenke, Director-Business Development
  • Ted Jenkins, Senior Director-Investor Relations

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Morgan Stanley (2.13%), BlackRock Inc. (2.05%), Geode Capital Management LLC (1.11%), Pinnacle Associates Ltd. (0.77%), Millennium Management LLC (0.54%) and Penserra Capital Management LLC (0.35%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends for Corbus Pharmaceuticals
.

Which institutional investors are selling Corbus Pharmaceuticals stock?

CRBP stock was sold by a variety of institutional investors in the last quarter, including Davy Global Fund Management Ltd, Millennium Management LLC, Bank of New York Mellon Corp, Citadel Advisors LLC, Dimensional Fund Advisors LP, Pinnacle Associates Ltd., HAP Trading LLC, and Jane Street Group LLC.
View insider buying and selling activity for Corbus Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Corbus Pharmaceuticals stock?

CRBP stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vident Investment Advisory LLC, Two Sigma Investments LP, Goldman Sachs Group Inc., Morgan Stanley, Penserra Capital Management LLC, LPL Financial LLC, and Geode Capital Management LLC. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Robert Paul Discordia, and Yuval Cohen.
View insider buying and selling activity for Corbus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $0.74.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals has a market capitalization of $92.67 million and generates $3.94 million in revenue each year. The biopharmaceutical company earns $-111.27 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Corbus Pharmaceuticals have?

Corbus Pharmaceuticals employs 76 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Where are Corbus Pharmaceuticals' headquarters?

Corbus Pharmaceuticals is headquartered at 500 River Ridge Drive, Norwood MA, 02062.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at [email protected], or via fax at 617-663-6085.


This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.